Close Menu

NEW YORK – Stanford University spinout Deepcell said on Monday that it has closed a $20 million Series A financing round.

Bow Capital led the round, joined by Andreessen Horowitz, which led Deepcell's $5 million seed round; 50Y; DCVC; Stanford University; and angel investors, including Jeff Dean, Senior VP of Google Research and Google Health.

Mountain View, California-based Deepcell said it would use the funding to continue development of its microfluidics-based cell sorting and analysis technology and to build a cell morphology atlas of more than 400 million cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.